• Skip to content (access key 1)
  • Skip to search (access key 7)
FWF — Austrian Science Fund
  • Go to overview page Discover

    • Research Radar
    • Discoveries
      • Emmanuelle Charpentier
      • Adrian Constantin
      • Monika Henzinger
      • Ferenc Krausz
      • Wolfgang Lutz
      • Walter Pohl
      • Christa Schleper
      • Anton Zeilinger
    • scilog Magazine
    • Awards
      • FWF Wittgenstein Awards
      • FWF START Awards
    • excellent=austria
      • Clusters of Excellence
      • Emerging Fields
    • In the Spotlight
      • 40 Years of Erwin Schrödinger Fellowships
      • Quantum Austria
    • Dialogs and Talks
      • think.beyond Summit
    • E-Book Library
  • Go to overview page Funding

    • Portfolio
      • excellent=austria
        • Clusters of Excellence
        • Emerging Fields
      • Projects
        • Principal Investigator Projects
        • Principal Investigator Projects International
        • Clinical Research
        • 1000 Ideas
        • Arts-Based Research
        • FWF Wittgenstein Award
      • Careers
        • ESPRIT
        • FWF ASTRA Awards
        • Erwin Schrödinger
        • Elise Richter
        • Elise Richter PEEK
        • doc.funds
        • doc.funds.connect
      • Collaborations
        • Specialized Research Groups
        • Special Research Areas
        • Research Groups
        • International – Multilateral Initiatives
        • #ConnectingMinds
      • Communication
        • Top Citizen Science
        • Science Communication
        • Book Publications
        • Digital Publications
        • Open-Access Block Grant
      • Subject-Specific Funding
        • AI Mission Austria
        • Belmont Forum
        • ERA-NET HERA
        • ERA-NET NORFACE
        • ERA-NET QuantERA
        • ERA-NET TRANSCAN
        • Alternative Methods to Animal Testing
        • European Partnership Biodiversa+
        • European Partnership ERA4Health
        • European Partnership ERDERA
        • European Partnership EUPAHW
        • European Partnership FutureFoodS
        • European Partnership OHAMR
        • European Partnership PerMed
        • European Partnership Water4All
        • Gottfried and Vera Weiss Award
        • netidee SCIENCE
        • Herzfelder Foundation Projects
        • Quantum Austria
        • Rückenwind Funding Bonus
        • Zero Emissions Award
      • International Collaborations
        • Belgium/Flanders
        • Germany
        • France
        • Italy/South Tyrol
        • Japan
        • Luxembourg
        • Poland
        • Switzerland
        • Slovenia
        • Taiwan
        • Tyrol–South Tyrol–Trentino
        • Czech Republic
        • Hungary
    • Step by Step
      • Find Funding
      • Submitting Your Application
      • International Peer Review
      • Funding Decisions
      • Carrying out Your Project
      • Closing Your Project
      • Further Information
        • Integrity and Ethics
        • Inclusion
        • Applying from Abroad
        • Personnel Costs
        • PROFI
        • Final Project Reports
        • Final Project Report Survey
    • FAQ
      • Project Phase PROFI
        • Accounting for Approved Funds
        • Labor and Social Law
        • Project Management
      • Project Phase Ad Personam
        • Accounting for Approved Funds
        • Labor and Social Law
        • Project Management
      • Expiring Programs
        • FWF START Awards
  • Go to overview page About Us

    • Mission Statement
    • FWF Video
    • Values
    • Facts and Figures
    • Annual Report
    • What We Do
      • Research Funding
        • Matching Funds Initiative
      • International Collaborations
      • Studies and Publications
      • Equal Opportunities and Diversity
        • Objectives and Principles
        • Measures
        • Creating Awareness of Bias in the Review Process
        • Terms and Definitions
        • Your Career in Cutting-Edge Research
      • Open Science
        • Open Access Policy
          • Open Access Policy for Peer-Reviewed Publications
          • Open Access Policy for Peer-Reviewed Book Publications
          • Open Access Policy for Research Data
        • Research Data Management
        • Citizen Science
        • Open Science Infrastructures
        • Open Science Funding
      • Evaluations and Quality Assurance
      • Academic Integrity
      • Science Communication
      • Philanthropy
      • Sustainability
    • History
    • Legal Basis
    • Organization
      • Executive Bodies
        • Executive Board
        • Supervisory Board
        • Assembly of Delegates
        • Scientific Board
        • Juries
      • FWF Office
    • Jobs at FWF
  • Go to overview page News

    • News
    • Press
      • Logos
    • Calendar
      • Post an Event
      • FWF Informational Events
    • Job Openings
      • Enter Job Opening
    • Newsletter
  • Discovering
    what
    matters.

    FWF-Newsletter Press-Newsletter Calendar-Newsletter Job-Newsletter scilog-Newsletter

    SOCIAL MEDIA

    • LinkedIn, external URL, opens in a new window
    • Twitter, external URL, opens in a new window
    • Facebook, external URL, opens in a new window
    • Instagram, external URL, opens in a new window
    • YouTube, external URL, opens in a new window

    SCILOG

    • Scilog — The science magazine of the Austrian Science Fund (FWF)
  • elane login, external URL, opens in a new window
  • Scilog external URL, opens in a new window
  • de Wechsle zu Deutsch

  

InSilify DrugTox

InSilify DrugTox

Martin Walter (ORCID: 0009-0007-3878-0224)
  • Grant DOI 10.55776/P37309
  • Funding program Principal Investigator Projects
  • Status ongoing
  • Start March 1, 2024
  • End February 29, 2028
  • Funding amount € 365,270
  • E-mail

Disciplines

Biology (25%); Computer Sciences (25%); Medical-Theoretical Sciences, Pharmacy (50%)

Keywords

    Computational Toxicology, 3R, Drug Development, QSAR

Abstract

In the project InSilify DrugTox, a large-scale retrospective computational toxicology (in silico) analysis will be performed with an extensive and pristine pool of toxicity data that originate from regulatory drug development and authorisation sources which have never been used for this purpose. The overarching aim of these computational toxicology investigations is to guide and support the regulatory transition towards drug development programs with a reduced demand of pre- and non-clinical animal studies. In short, the aim of the project is to InSilify Drug development through computational Toxicology. This endeavour will be achieved by a collaboration of scientific and regulatory experts of three renowned Austrian institutions (the Austrian Medicines and Medical Devices Agency, the Pharmacoinformatics Research Group of the University of Vienna, and the Regulatory Toxicology Group of the Medical University of Innsbruck). Specifically relevant for InSilify is the fact that toxicology in silico modelling bears a high potential to replace animal studies during drug development. However, in order to receive regulatory acceptance, these models need to deliver safe and accurate prediction outputs. The retrospective modelling analysis of InSilify will inform whether the replacement and reduction of animal studies with potent computational in silico models is safe and fit-for-use. An important advantage of InSilify is that the data used for modelling originate from regulatory drug development and authorisation sources. It is therefore expected that the results gathered in this project will receive high regulatory attention and acceptance, which may directly translate into a rapid implementation of in silico models into regulatory drug frameworks for toxicity endpoints for which a sufficient extent of prediction accuracy has been obtained in the project. A rapid regulatory implementation of computational toxicology modelling will directly correlate with a replacement of pre- and nonclinical animal studies in drug development. If the retrospective analyses of InSilify demonstrate that particular toxicity endpoints cannot yet be predicted with sufficient accuracy, this outcome will point out weaknesses of the currently available toxicology models. Reporting these weaknesses is anticipated to stimulate developers to refine their models, which on the longer run will also directly support the implementation of computational toxicology in drug development. Finally, apart from the high potential to replace animal studies by in silico toxicology, an increased implementation of accurate and fit-for-use in silico models in drug development will directly lead to cost reductions and faster development durations of drug candidates for patients which suffer from an unmet medical need. The results of InSilify will support this process.

Research institution(s)
  • AGES - Österreichische Agentur für Gesundheit und Ernährungssicherheit - 100%
Project participants
  • Alexandra Schaffert, Medizinische Universität Innsbruck , national collaboration partner
  • Martin Paparella, Medizinische Universität Innsbruck , national collaboration partner
  • Gerhard F. Ecker, Universität Wien , national collaboration partner

Discovering
what
matters.

Newsletter

FWF-Newsletter Press-Newsletter Calendar-Newsletter Job-Newsletter scilog-Newsletter

Contact

Austrian Science Fund (FWF)
Georg-Coch-Platz 2
(Entrance Wiesingerstraße 4)
1010 Vienna

office(at)fwf.ac.at
+43 1 505 67 40

General information

  • Job Openings
  • Jobs at FWF
  • Press
  • Philanthropy
  • scilog
  • FWF Office
  • Social Media Directory
  • LinkedIn, external URL, opens in a new window
  • Twitter, external URL, opens in a new window
  • Facebook, external URL, opens in a new window
  • Instagram, external URL, opens in a new window
  • YouTube, external URL, opens in a new window
  • Cookies
  • Whistleblowing/Complaints Management
  • Accessibility Statement
  • Data Protection
  • Acknowledgements
  • Social Media Directory
  • © Österreichischer Wissenschaftsfonds FWF
© Österreichischer Wissenschaftsfonds FWF